| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| L Wu, W Nicholson, C-Y Wu, M Xu, A McGaha, M Shiota, A C Power. Engineering physiologically regulated insulin secretion in non-beta cells by expressing glucagon-like peptide 1 receptor. Gene therapy. vol 10. issue 19. 2003-09-17. PMID:12923570. |
glucagon-like peptide 1 (glp-1) is released from neuroendocrine cells in the intestine in the postprandial state and augments glucose-stimulated insulin secretion from pancreatic beta cells. |
2003-09-17 |
2023-08-12 |
mouse |
| L Wu, W Nicholson, C-Y Wu, M Xu, A McGaha, M Shiota, A C Power. Engineering physiologically regulated insulin secretion in non-beta cells by expressing glucagon-like peptide 1 receptor. Gene therapy. vol 10. issue 19. 2003-09-17. PMID:12923570. |
to develop non-beta cells that exhibit physiologically regulated insulin secretion, we coexpressed the glp-1 receptor and human insulin in primary rat pituitary cells using adenovirus-mediated gene transfer. |
2003-09-17 |
2023-08-12 |
mouse |
| L Wu, W Nicholson, C-Y Wu, M Xu, A McGaha, M Shiota, A C Power. Engineering physiologically regulated insulin secretion in non-beta cells by expressing glucagon-like peptide 1 receptor. Gene therapy. vol 10. issue 19. 2003-09-17. PMID:12923570. |
when both the glp-1 receptor and human insulin were introduced, glp-1 stimulated cosecretion of human insulin and endogenous pituitary hormones. |
2003-09-17 |
2023-08-12 |
mouse |
| L Wu, W Nicholson, C-Y Wu, M Xu, A McGaha, M Shiota, A C Power. Engineering physiologically regulated insulin secretion in non-beta cells by expressing glucagon-like peptide 1 receptor. Gene therapy. vol 10. issue 19. 2003-09-17. PMID:12923570. |
after transplantation of pituitary cells coexpressing human insulin and glp-1 receptor into mice, enteral glucose stimulated insulin secretion. |
2003-09-17 |
2023-08-12 |
mouse |
| Suzanne G Laychock, Yingrao Tian, Shawn M Sessann. Endothelial differentiation gene receptors in pancreatic islets and INS-1 cells. Diabetes. vol 52. issue 8. 2003-09-15. PMID:12882914. |
stimulation of edg receptors in islets and ins-1 cells with spp inhibited glucagon-like peptide 1 (glp-1)-stimulated camp production and insulin secretion in a concentration-dependent manner. |
2003-09-15 |
2023-08-12 |
mouse |
| Suzanne G Laychock, Yingrao Tian, Shawn M Sessann. Endothelial differentiation gene receptors in pancreatic islets and INS-1 cells. Diabetes. vol 52. issue 8. 2003-09-15. PMID:12882914. |
thus, edg receptors are expressed in pancreatic islet beta-cells and g(i) seems to mediate the inhibition by spp of adenylyl cyclase and camp formation and inhibition of the stimulation of insulin secretion by glp-1. |
2003-09-15 |
2023-08-12 |
mouse |
| Shaista Quddusi, Torsten P Vahl, Kevin Hanson, Ronald L Prigeon, David A D'Alessi. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes care. vol 26. issue 3. 2003-09-11. PMID:12610039. |
the purpose of this study was to determine whether an extended infusion of the incretin hormone glucagon-like peptide 1 (glp-1) has a greater effect to promote insulin secretion in type 2 diabetic subjects than acute administration of the peptide. |
2003-09-11 |
2023-08-12 |
human |
| Jesús Cancelas, Verónica Sancho, Maria L Villanueva-Peñacarrillo, Philippe Courtois, Fraser W Scott, Isabel Valverde, Willy J Malaiss. Glucagon-like peptide 1 content of intestinal tract in adult rats injected with streptozotocin either during neonatal period or 7 d before sacrifice. Endocrine. vol 19. issue 3. 2003-09-02. PMID:12624427. |
the findings recorded in the rats injected with stz either during the neonatal period or later in life indicate that hyperglycemia and/or insulin deficiency do not cause a decrease in glp-1 content of the intestinal tract. |
2003-09-02 |
2023-08-12 |
rat |
| Philip J Larsen, Niels Vrang, Mads Tang-Christense. Central pre-proglucagon derived peptides: opportunities for treatment of obesity. Current pharmaceutical design. vol 9. issue 17. 2003-08-22. PMID:12769729. |
in the periphery, pre-proglucagon derived peptides, glucagon-like peptide-1 (glp-1), glucagon-like peptide-2 (glp-2) and oxyntomodulin (oxm) are involved in a wide variety of physiological functions, including glucose homeostasis, gastric emptying, intestinal growth, insulin secretion as well as the regulation of food intake. |
2003-08-22 |
2023-08-12 |
Not clear |
| Annette M Chang, Grethe Jakobsen, Jeppe Sturis, Marla J Smith, Cathie J Bloem, Bob An, Andrzej Galecki, Jeffrey B Halte. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes. vol 52. issue 7. 2003-08-19. PMID:12829647. |
glucagon-like peptide 1 (glp-1) stimulates insulin secretion in a glucose-dependent manner, but its short half-life limits its therapeutic potential. |
2003-08-19 |
2023-08-12 |
human |
| B Messenger, M N Clifford, L M Morga. Glucose-dependent insulinotropic polypeptide and insulin-like immunoreactivity in saliva following sham-fed and swallowed meals. The Journal of endocrinology. vol 177. issue 3. 2003-08-11. PMID:12773121. |
salivary and plasma levels of immunoreactive insulin, gip and glucagon-like peptide-1 (glp-1), total protein, alpha-amylase, glucose and non-esterified fatty acid were measured before and for 90 min following the meals. |
2003-08-11 |
2023-08-12 |
human |
| Michael Mar. NN-2211 Novo Nordisk. IDrugs : the investigational drugs journal. vol 6. issue 3. 2003-08-01. PMID:12789615. |
novo nordisk a/s, under license from scios inc, is developing nn-2211, a stable analog of the naturally occurring peptide hormone glucagon-like peptide 1 (glp-1), which stimulates insulin release in response to increases in blood sugar levels, for the potential treatment of type 2 diabetes. |
2003-08-01 |
2023-08-12 |
Not clear |
| Younes Anini, Patricia L Brubake. Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells. Endocrinology. vol 144. issue 7. 2003-07-22. PMID:12810581. |
glucagon-like peptide 1 (glp-1) released from distal intestinal endocrine l cells after food intake is a potent glucose-dependent stimulant of insulin secretion. |
2003-07-22 |
2023-08-12 |
human |
| Susanne G Straub, Geoffrey W G Shar. Glucose-stimulated signaling pathways in biphasic insulin secretion. Diabetes/metabolism research and reviews. vol 18. issue 6. 2003-07-17. PMID:12469359. |
agonists that can change the rate-limiting steps for both phases of insulin release include those like glucagon-like peptide 1 (glp-1) that raise cyclic amp levels and those like acetylcholine that act via dag. |
2003-07-17 |
2023-08-12 |
mouse |
| Paul E Wiedeman, James M Trevillya. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes. Current opinion in investigational drugs (London, England : 2000). vol 4. issue 4. 2003-07-17. PMID:12808880. |
glucagon-like peptide-1 (glp-1 (7-36) amide) is a gut hormone released from l-cells in the small intestine in response to the ingestion of nutrients and enhances the glucose-dependent secretion of insulin from pancreatic beta-cells. |
2003-07-17 |
2023-08-12 |
Not clear |
| G S Frost, A E Brynes, W S Dhillo, S R Bloom, M I McBurne. The effects of fiber enrichment of pasta and fat content on gastric emptying, GLP-1, glucose, and insulin responses to a meal. European journal of clinical nutrition. vol 57. issue 2. 2003-07-16. PMID:12571662. |
the effects of fiber enrichment of pasta and fat content on gastric emptying, glp-1, glucose, and insulin responses to a meal. |
2003-07-16 |
2023-08-12 |
Not clear |
| G S Frost, A E Brynes, W S Dhillo, S R Bloom, M I McBurne. The effects of fiber enrichment of pasta and fat content on gastric emptying, GLP-1, glucose, and insulin responses to a meal. European journal of clinical nutrition. vol 57. issue 2. 2003-07-16. PMID:12571662. |
to assess whether the addition of viscous fiber at an amount recommended by the us fda to allow a 'low saturated fat, cholesterol, soluble fiber and coronary heart disease', health claim label on a food package (1.7 g psyllium) and/or fat (30 g sunflower oil and 3 g sodium propionate) to a pasta meal would affect gastric emptying, postprandial glucose, insulin and glp-1 concentrations. |
2003-07-16 |
2023-08-12 |
Not clear |
| Stacey L Conarello, Zhihua Li, John Ronan, Ranabir Sinha Roy, Lan Zhu, Guoqiang Jiang, Franklin Liu, John Woods, Emanuel Zycband, David E Moller, Nancy A Thornberry, Bei B Zhan. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America. vol 100. issue 11. 2003-07-16. PMID:12748388. |
ablation of dp-iv also is associated with elevated glp-1 levels and improved metabolic control in these animals, resulting in improved insulin sensitivity, reduced pancreatic islet hypertrophy, and protection against streptozotocin-induced loss of beta cell mass and hyperglycemia. |
2003-07-16 |
2023-08-12 |
mouse |
| Daniel M Kemp, Mariano Ubeda, Joel F Habene. Identification and functional characterization of melatonin Mel 1a receptors in pancreatic beta cells: potential role in incretin-mediated cell function by sensitization of cAMP signaling. Molecular and cellular endocrinology. vol 191. issue 2. 2003-07-11. PMID:12062899. |
acute melatonin treatment of ins-1 cells in the presence of either forskolin or the incretin hormone glucagon-like peptide 1 (glp-1) caused an attenuation of the responses in insulin secretion, insulin promoter activity, and cre mediated gene expression, consistent with its effects in inhibiting camp mediated signal transduction. |
2003-07-11 |
2023-08-12 |
rat |
| Daniel M Kemp, Mariano Ubeda, Joel F Habene. Identification and functional characterization of melatonin Mel 1a receptors in pancreatic beta cells: potential role in incretin-mediated cell function by sensitization of cAMP signaling. Molecular and cellular endocrinology. vol 191. issue 2. 2003-07-11. PMID:12062899. |
in isolated rat islets, insulin secretion was enhanced following melatonin pre-treatment both in the absence and presence of glp-1 or forskolin. |
2003-07-11 |
2023-08-12 |
rat |